Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs).

被引：0
|
作者：
Dasari, Arvind
Li, Daneng
Sung, Max W.
Tucci, Christopher
Kauh, John S.
Kania, Marek K.
Paulson, Andrew Scott
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] City Hope Comprehens Canc Ctr, Dept Med Oncol, Duarte, CA USA
[3] Beckman Res Inst, Duarte, CA USA
[4] Tisch Canc Inst Mt Sinai, New York, NY USA
[5] Hutchison MediPharma, Florham Pk, NJ USA
[6] Eli Lilly & Co, Bridgewater, NJ USA
[7] Hutchison MediPharma Int Inc, Florham Pk, NJ USA
[8] Texas Oncol US Oncol Network, Dallas, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4610
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Interim analysis results of surufatinib in US patients with neuroendocrine tumors (NETs).
    Paulson, Andrew Scott
    Li, Daneng
    Sung, Max W.
    Tucci, Christopher
    Kauh, John S.
    Nanda, Shivani
    Kania, Marek K.
    Dasari, Arvind
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Interim Analysis Results of Surufatinib in US Patients With Neuroendocrine Tumors (NETs)
    Li, Daneng
    Paulson, Andrew
    Tucci, Christopher
    Kauh, John
    Nanda, Shivani
    Kania, Marek
    Dasari, Arvind
    PANCREAS, 2022, 51 (03) : E36 - E37
  • [3] Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)
    Dasari, A.
    Paulson, S.
    Sung, M.
    Tucci, C.
    Kauh, J.
    Kania, M.
    Li, D.
    NEUROENDOCRINOLOGY, 2020, 110 : 209 - 209
  • [4] A phase 2 study to evaluate the efficacy and safety of SU 11248 in patients (pts) with unresectable neuroendocrine tumors (NETs)
    Kulke, M
    Lenz, HJ
    Meropol, NJ
    Posey, J
    Ryan, DP
    Picus, J
    Bergsland, E
    Stuart, K
    Baum, CM
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 310S - 310S
  • [5] Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)
    Xu, Jianming
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [6] Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs) in a United States (US) Population
    Katona, Bryson W.
    Riff, Brian P.
    Soulen, Michael C.
    Pryma, Daniel A.
    Bennett, Bonita J.
    Wild, Damian
    Nicolas, Guillaume
    Teitelbaum, Ursina R.
    Metz, David C.
    GASTROENTEROLOGY, 2016, 150 (04) : S208 - S209
  • [7] Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)
    Xu, J.
    Shen, L.
    Zhou, Z.
    Li, J.
    Bai, C.
    Chi, Y.
    Li, Z.
    Xu, N.
    Jia, R.
    Li, E.
    Liu, T.
    Bai, Y.
    Yuan, Y.
    Li, X.
    Wang, X.
    Chen, J.
    Ying, J.
    Li, J.
    Fan, S.
    Su, W.
    ANNALS OF ONCOLOGY, 2019, 30 : 911 - 911
  • [8] A phase II study of pemetrexed in patients (pts) with advanced neuroendocrine tumors (NETs)
    Bhargava, P.
    Earle, C. C.
    Zhu, A. X.
    Clark, J. W.
    Vincitore, M.
    Battu, S.
    Regan, E.
    Lawrence, C.
    Kulke, M. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study
    Long, J.
    Wu, C.
    Hu, B.
    Tao, C.
    Gu, H.
    Dong, H.
    Yan, J.
    Qi, Z.
    Zhao, C.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S958 - S958
  • [10] Safety and Efficacy of Everolimus in Adult Patients with Neuroendocrine Tumors
    Oberstein, Paul E.
    Saif, M. Wasif
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6 : 41 - 51
12345